Encorafenib in combination with binimetinib is in development for the treatment of BRAF V600E mutant non-small-cell lung cancer (NSCLC). The BRAF gene encodes for a protein, also called BRAF, a protein involved in stimulating cell division. A common mutation to this gene is ‘V600’. This abnormal form of BRAF plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells. Blocking the action of the abnormal BRAF helps to slow down the growth and spread of the cancer. There is currently no National Institute for Health and Care Excellence (NICE) recommended treatment options for this specific indication, highlighting the need for a therapy.
Encorafenib with binimetinib for treating metastatic BRAF V600E mutant non-small-cell lung cancer
Encorafenib in combination with binimetinib is in development for the treatment of BRAF V600E mutant non-small-cell lung cancer (NSCLC). The BRAF gene encodes for a protein, also called BRAF, a protein involved in stimulating cell division. A common mutation to this gene is ‘V600’. This abnormal form of BRAF plays a role in the development of the cancer by allowing uncontrolled division of the tumour cells.
Indications:
Non-small-cell lung cancer (NSCLC)
Therapeutic Areas:
Lung and Respiratory Cancer
Year:
2022